Treatment with Romidepsin, a bicyclic class 1 selective HDAC inhibitor, has been shown to increase the expression of CCL5, CXCL9, and CXCL10 in tumor cells, promoting T cell recruitment into the tumor site and boost T cell-mediated anti-tumor function in multiple lung tumor models [132]. Here, CCL5 is linked to neoplasm.